Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...

EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease ...

Distant metastasis in head and neck cancer: Baseline factors. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include a full text component.

Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.

Tissue factor (TF), a transmembrane protein overexpressed in tumors such as cervical, head and neck, NSCLC, and pancreatic cancers, initiates the extrinsic coagulation pathway under normal ...